Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
ANSWER cohort
Biological disease-modifying antirheumatic drugs
Drug retention
Rheumatoid arthritis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
15 06 2020
15 06 2020
Historique:
received:
23
01
2020
accepted:
02
06
2020
entrez:
17
6
2020
pubmed:
17
6
2020
medline:
22
6
2021
Statut:
epublish
Résumé
This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of 7 biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib (TOF), one of the janus kinase inhibitors, in bDMARDs-naïve and bDMARDs-switched patients with rheumatoid arthritis (RA). This study assessed 3897 patients and 4415 treatment courses with bDMARDs and TOF from 2001 to 2019 (2737 bDMARDs-naïve courses and 1678 bDMARDs-switched courses [59.5% of switched courses were their second agent], female 82.3%, baseline age 57.4 years, disease duration 8.5 years; rheumatoid factor positivity 78.4%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate 4.3; concomitant prednisolone [PSL] dose 6.1 mg/day [usage 42.4%], and methotrexate [MTX] dose 8.5 mg/week [usage 60.9%]). Treatment courses included abatacept (ABT; n = 663), adalimumab (ADA; n = 536), certolizumab pegol (CZP; n = 226), etanercept (ETN; n = 856), golimumab (GLM; n = 458), infliximab (IFX; n = 724), tocilizumab (TCZ; n = 851), and TOF (n = 101/only bDMARDs-switched cases). Drug discontinuation reasons (categorized into lack of effectiveness, toxic adverse events, non-toxic reasons, or remission) and rates were estimated at 36 months using Gray's test and statistically evaluated after adjusted by potential clinical confounders (age, sex, disease duration, concomitant PSL and MTX usage, starting date, and number of switched bDMARDs) using the Fine-Gray model. Cumulative incidence of drug discontinuation for each reason was as follows: lack of effectiveness in the bDMARDs-naïve group (from 13.7% [ABT] to 26.9% [CZP]; P < 0.001 between agents) and the bDMARDs-switched group (from 18.9% [TCZ] to 46.1% [CZP]; P < 0.001 between agents); toxic adverse events in the bDMARDs-naïve group (from 4.6% [ABT] to 11.2% [ETN]; P < 0.001 between agents) and the bDMARDs-switched group (from 5.0% [ETN] to 15.7% [TOF]; P = 0.004 between agents); and remission in the bDMARDs-naïve group (from 2.9% [ETN] to 10.0% [IFX]; P < 0.001 between agents) and the bDMARDs-switched group (from 1.1% [CZP] to 3.3% [GLM]; P = 0.9 between agents). Remarkable differences were observed in drug retention of 7 bDMARDs and TOF between bDMARDs-naïve and bDMARDs-switched cases.
Sections du résumé
BACKGROUND
This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of 7 biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib (TOF), one of the janus kinase inhibitors, in bDMARDs-naïve and bDMARDs-switched patients with rheumatoid arthritis (RA).
METHODS
This study assessed 3897 patients and 4415 treatment courses with bDMARDs and TOF from 2001 to 2019 (2737 bDMARDs-naïve courses and 1678 bDMARDs-switched courses [59.5% of switched courses were their second agent], female 82.3%, baseline age 57.4 years, disease duration 8.5 years; rheumatoid factor positivity 78.4%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate 4.3; concomitant prednisolone [PSL] dose 6.1 mg/day [usage 42.4%], and methotrexate [MTX] dose 8.5 mg/week [usage 60.9%]). Treatment courses included abatacept (ABT; n = 663), adalimumab (ADA; n = 536), certolizumab pegol (CZP; n = 226), etanercept (ETN; n = 856), golimumab (GLM; n = 458), infliximab (IFX; n = 724), tocilizumab (TCZ; n = 851), and TOF (n = 101/only bDMARDs-switched cases). Drug discontinuation reasons (categorized into lack of effectiveness, toxic adverse events, non-toxic reasons, or remission) and rates were estimated at 36 months using Gray's test and statistically evaluated after adjusted by potential clinical confounders (age, sex, disease duration, concomitant PSL and MTX usage, starting date, and number of switched bDMARDs) using the Fine-Gray model.
RESULTS
Cumulative incidence of drug discontinuation for each reason was as follows: lack of effectiveness in the bDMARDs-naïve group (from 13.7% [ABT] to 26.9% [CZP]; P < 0.001 between agents) and the bDMARDs-switched group (from 18.9% [TCZ] to 46.1% [CZP]; P < 0.001 between agents); toxic adverse events in the bDMARDs-naïve group (from 4.6% [ABT] to 11.2% [ETN]; P < 0.001 between agents) and the bDMARDs-switched group (from 5.0% [ETN] to 15.7% [TOF]; P = 0.004 between agents); and remission in the bDMARDs-naïve group (from 2.9% [ETN] to 10.0% [IFX]; P < 0.001 between agents) and the bDMARDs-switched group (from 1.1% [CZP] to 3.3% [GLM]; P = 0.9 between agents).
CONCLUSIONS
Remarkable differences were observed in drug retention of 7 bDMARDs and TOF between bDMARDs-naïve and bDMARDs-switched cases.
Identifiants
pubmed: 32539813
doi: 10.1186/s13075-020-02232-w
pii: 10.1186/s13075-020-02232-w
pmc: PMC7296929
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Pharmaceutical Preparations
0
Piperidines
0
Pyrimidines
0
tofacitinib
87LA6FU830
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
142Références
Arthritis Res Ther. 2018 Aug 3;20(1):165
pubmed: 30075810
Arthritis Res Ther. 2019 Apr 11;21(1):91
pubmed: 30971306
RMD Open. 2017 Jan 3;3(1):e000363
pubmed: 28123781
Rheumatol Int. 2020 Feb;40(2):217-225
pubmed: 31620864
Rheumatology (Oxford). 2016 Mar;55(3):523-34
pubmed: 26490106
Ann Rheum Dis. 2010 Jan;69(1):88-96
pubmed: 19297346
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Rheumatology (Oxford). 2015 Jul;54(7):1186-93
pubmed: 25505001
Ann Rheum Dis. 2012 Jun;71(6):997-9
pubmed: 22294628
Arthritis Rheumatol. 2016 Jan;68(1):56-66
pubmed: 26315675
Rheumatology (Oxford). 2011 Jan;50(1):117-23
pubmed: 20671021
Ann Rheum Dis. 2012 Jul;71(7):1134-42
pubmed: 22294625
Ann Rheum Dis. 2017 Jun;76(6):1101-1136
pubmed: 28298374
Rheumatology (Oxford). 2015 Sep;54(9):1664-72
pubmed: 25922549
Semin Arthritis Rheum. 2018 Aug;48(1):22-27
pubmed: 29422324
Int J Rheum Dis. 2016 Nov;19(11):1103-1111
pubmed: 26692536
Ann Rheum Dis. 2015 Feb;74(2):354-60
pubmed: 24285495
Ann Rheum Dis. 2011 Jul;70(7):1216-22
pubmed: 21551512
Ann Rheum Dis. 2004 Nov;63 Suppl 2:ii13-ii17
pubmed: 15479864
Rheumatology (Oxford). 2011 Jan;50(1):204-13
pubmed: 21084326
PLoS One. 2018 Mar 15;13(3):e0194130
pubmed: 29543846
Mod Rheumatol. 2007;17(6):451-8
pubmed: 18084695
Mod Rheumatol. 2009;19(4):351-7
pubmed: 19590933
Drugs Real World Outcomes. 2018 Sep;5(3):169-179
pubmed: 30073580
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Rheumatology (Oxford). 2015 Dec;54(12):2156-65
pubmed: 26175471
RMD Open. 2017 Jan 17;3(1):e000314
pubmed: 28123776
Arthritis Rheum. 2009 May 15;61(5):560-8
pubmed: 19405000
Ann Rheum Dis. 2005 Aug;64(8):1220-3
pubmed: 15640272
Clin Rheumatol. 2020 Mar 11;:
pubmed: 32162152
Rheumatology (Oxford). 2014 Sep;53(9):1664-8
pubmed: 24729445
Clin Ther. 2016 Dec;38(12):2628-2641.e5
pubmed: 27889300
Bone Marrow Transplant. 2007 Aug;40(4):381-7
pubmed: 17563735
Scand J Rheumatol. 2013;42(4):253-9
pubmed: 23470089
Ann Rheum Dis. 2010 Sep;69(9):1580-8
pubmed: 20699241
Arthritis Res Ther. 2016 Dec 1;18(1):280
pubmed: 27906048
Nat Rev Rheumatol. 2015 May;11(5):276-89
pubmed: 25687177
PLoS One. 2019 May 8;14(5):e0216624
pubmed: 31067271
Nihon Rinsho. 2016 Jun;74(6):939-43
pubmed: 27311182
Radiother Oncol. 2019 Jan;130:185-189
pubmed: 30314718
Arthritis Care Res (Hoboken). 2016 Apr;68(4):432-9
pubmed: 26556048
Arthritis Rheum. 2010 Jan;62(1):22-32
pubmed: 20039405